Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death [0.03%]
高死亡风险肺动脉高压患者中的Sotatercept治疗
Marc Humbert,Vallerie V McLaughlin,David B Badesch et al.
Marc Humbert et al.
Background: Sotatercept improves exercise capacity and delays the time to clinical worsening in patients with World Health Organization (WHO) functional class II or III pulmonary arterial hypertension. The effects of add-...
Tobias Reichlin,Thomas Kueffer,Patrick Badertscher et al.
Tobias Reichlin et al.
Background: Pulmonary-vein isolation is an effective treatment for paroxysmal atrial fibrillation. Pulsed field ablation (PFA) is a nonthermal ablation method with few adverse effects beyond the myocardium. Data are lacki...
Routine Cerebral Embolic Protection during Transcatheter Aortic-Valve Implantation [0.03%]
经导管主动脉瓣植入术中常规进行脑栓塞保护
Rajesh K Kharbanda,James Kennedy,Zahra Jamal et al.
Rajesh K Kharbanda et al.
Background: Transcatheter aortic-valve implantation (TAVI) is associated with procedure-related stroke. Cerebral embolic protection (CEP) devices may reduce embolization to the cerebral circulation and hence the incidence...
Simon Noble
Simon Noble
Global Cardiovascular Risk Consortium;Christina Magnussen,Jesus Alegre-Diaz,Lubna A Al-Nasser et al.
Global Cardiovascular Risk Consortium;Christina Magnussen et al.
Background: Five risk factors account for approximately 50% of the global burden of cardiovascular disease. How the presence or absence of classic risk factors affects lifetime estimates of cardiovascular disease and deat...
Alexander A Iyer,David A Hirsh,Richard M Schwartzstein
Alexander A Iyer
Danielle B Holt,Eric A Elster
Danielle B Holt
Lepodisiran - A Long-Duration Small Interfering RNA Targeting Lipoprotein(a) [0.03%]
Lepodisiran - 长效小干扰RNA，靶向脂蛋白(a)
Steven E Nissen,Wei Ni,Xi Shen et al.
Steven E Nissen et al.
Background: Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting hepatic synthesi...
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes [0.03%]
高风险2型糖尿病患者的心血管结局与口服司美格鲁肽的关系
Darren K McGuire,Nikolaus Marx,Sharon L Mulvagh et al.
Darren K McGuire et al.
Background: The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the cardiovascular...
Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation [0.03%]
经导管主动脉瓣植入患者的达格列净治疗
Sergio Raposeiras-Roubin,Ignacio J Amat-Santos,Xavier Rossello et al.
Sergio Raposeiras-Roubin et al.
Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of heart-failure admission among high-risk patients. However, most patients with valvular heart disease, including those undergoing transcathet...